Szűcs Anna, Horváth András, Kamondi Anita
Ideggyogy Sz. 2015 Jan 30;68(1-2):23-9.
A retrospective study in adult partial epilepsy on the efficacy of lacosamide in relation to previous antiepileptic drug experiences.
We analysed 3-65 months' data on epilepsy-care of 43 pharmacoresistant partial epilepsy patients treated with lacosamide. Further analysis of antiepileptic drug history was carried out in strictly selected subgroups of patients with good and poor therapeutic response to lacosamide (10 and 9 patients, respectively) for 2-10 years long retrospective follow up.
Adult patients with partial-onset seizures had been treated previously with three or more lifetime antiepileptic drugs without permanent success.
Six patients (14%) were seizure free, eleven patients (25%) have experienced important improvement (their seizure-frequency decreased by at least 50%) for more than 12 months. Fourteen patients (32%) improved for less than 6 months and then have relapsed; and add-on lacosamide proved ineffective in 12 patients (28%). Those selected 10 patients successfully treated with lacosamide (seizure free for at least six months) favourably responded to carbamazepine or oxcarbazepine earlier and levetiracetam was ineffective or even caused worsening. The selected lacosamide-unresponsive nine patients responded unfavourably to carbamazepine or oxcarbazepine earlier. Fifteen patients (35%) suffered side effects as dizziness or sleepiness, in 11 of them lacosamide was combined with a "traditional" sodium-channal blocker antiepileptic drug.
Lacosamide is an effective add-on antiepileptic drug in difficult-to treat adult partial epilepsy patients. Our data suggest that good lacosamide response may be expected in those patients who reacted favourably to "traditional" sodium-channel blocker carbamazepine or oxcarbazepine earlier.
对成年部分性癫痫患者进行一项回顾性研究,探讨拉科酰胺相对于既往抗癫痫药物治疗经历的疗效。
我们分析了43例接受拉科酰胺治疗的药物难治性部分性癫痫患者3至65个月的癫痫治疗数据。对拉科酰胺治疗反应良好和不佳的患者(分别为10例和9例)进行严格筛选的亚组分析,进行为期2至10年的回顾性随访,并进一步分析抗癫痫药物治疗史。
成年部分性发作癫痫患者此前曾接受过三种或更多种终身抗癫痫药物治疗,但未取得永久性成功。
6例患者(14%)无癫痫发作,11例患者(25%)有显著改善(癫痫发作频率至少降低50%)超过12个月。14例患者(32%)改善不足6个月后复发;12例患者(28%)加用拉科酰胺无效。那10例成功接受拉科酰胺治疗(无癫痫发作至少6个月)的患者早期对卡马西平或奥卡西平反应良好,而左乙拉西坦无效甚至导致病情恶化。那9例对拉科酰胺无反应的患者早期对卡马西平或奥卡西平反应不佳。15例患者(35%)出现头晕或嗜睡等副作用,其中11例患者拉科酰胺与一种“传统”钠通道阻滞剂抗癫痫药物联用。
拉科酰胺是治疗难治性成年部分性癫痫患者的一种有效附加抗癫痫药物。我们的数据表明,那些早期对“传统”钠通道阻滞剂卡马西平或奥卡西平反应良好的患者可能对拉科酰胺反应良好。